Compounding and the limits of a draft policy
A compounded drug comes from a pharmacist or doctor preparing it, or from a registered facility. It is different from a finished product supplied under an approval. Ask why that preparation is being proposed for your care. Keep its exact ingredient, form (such as a tablet or injection) and intended use in view. A broad claim about “peptides” cannot answer a question about a particular preparation.
The Food and Drug Administration (FDA) grants no approval to compounded drugs. Product quality, treatment results and safety receive no FDA assessment before market entry; this position was checked November 3, 2026.
503A names the part of federal law for medicines made for a patient identified by name. As of November 3, 2026, it requires a valid prescription for that patient. Having a prescription does not by itself show that the preparation meets every requirement in that law. A licensed pharmacist at a state-licensed pharmacy or federal facility, or a licensed physician, makes the drug.
A separate part of that law, 503B, covers facilities registered with FDA that make sterile drugs. A sterile medicine has no living germs. As of November 3, 2026, this part does not require a prescription in the patient’s name.
These names identify parts of federal law; they are not quality scores. Ask the pharmacy which part it relies on and where its record can be found.
The federal department Health and Human Services, or HHS, issued its notice about certain compounded peptide medicines on October 30, 2026. It describes the policy as a nonbinding draft. The legal requirements stay in place.
The draft describes when HHS plans not to act against compounding with these ingredients. All ten conditions must be met. It concerns medicine made by state-licensed pharmacies and physicians for the person identified in the prescription. Having that prescription meets only part of the policy.
Six names fall within that scope: MOTS-c, KPV, TB-500, semax, BPC-157 and epitalon.
It covers preparations containing just one peptide ingredient. Only the chemical versions named in the draft are covered. The way the medicine is given must also match the draft. It excludes peptide blends and 503B facilities.
If the proposal combines peptides, ask which rule is being cited for that mix. Keep that answer with the full ingredient list. Ask which parts of the policy support the plan in front of you.
The official raw-ingredient list for 503A includes none of these six peptides. The draft does not give any of them FDA approval. It does not give pharmacies or doctors a new right to prepare them. A plan to hold back enforcement does not change what the law allows.
A “bulks list” is a list of raw drug ingredients. Ask for the part of the policy that is said to cover the exact preparation under discussion.
To nominate an ingredient is to ask FDA to consider it for the compounding list. FDA lists withdrawn requests separately. FDA still lists safety concerns about those withdrawn ingredients. Its page marks April 22, 2026 as the date the information is current.
Taking a request back does not clear an ingredient for compounding. It also does not add it to the separate group covered by FDA’s usual policy of choosing not to take enforcement action under 503A. The agency gives no withdrawal date for each substance.
HHS’s account published with the October 30, 2026 policy describes votes at the committee’s July 2026 meeting. It reports votes in favor of six of the seven peptides considered. Those votes gave advice; they did not change the ingredient list.
An advisory committee gives advice. Its vote and a rule that changes the list are different events. Keep the dated policy document beside any headline about a vote.
In its statement checked November 4, 2026, the Kansas pharmacy board describes limits on compounded copies. The drug must be on the national shortage list or the change must make a clinically significant difference for the named patient. Here, clinically significant means the change matters for that person’s medical care. A prefilled checkbox prescription may not meet the requirements.
Ask what change is proposed, what need it addresses and how it will be documented. A reply that only repeats the advertisement leaves those questions open. Take a product-specific uncertainty back to the prescriber and pharmacist. The weight-care page covers the different rules around copies of approved weight and diabetes medicines.